What are Antacid and antiemetic combination drugs?

Antacid and antiemetic combination drugs are pharmacologic agents that share a common mechanism (typically targeting 5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)). 2 are currently marketed, with 5 more in clinical development.

What are the marketed Antacid and antiemetic combination drugs?

Marketed Antacid and antiemetic combination drugs include Sodium Bicarbonate Powder and ondansetron, Dexamethasone, Ondansetron, Aprepitant.

Antacid and antiemetic combination

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed 4 in Phase 3 1 in Phase 2

This page covers all Antacid and antiemetic combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate), Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor, 5-HT3 receptors, glucocorticoid receptors.

Targets

5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate) · Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor · 5-HT3 receptors, glucocorticoid receptors · Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor · NK1 receptor, 5-HT3 receptor, glucocorticoid receptor · 5-HT3 receptor, NK1 receptor, glucocorticoid receptor

Marketed (2)

Sodium Bicarbonate Powder and ondansetron · Aya Sabry Mohamed Mohamed · Gastroenterology
This combination uses sodium bicarbonate to neutralize gastric acid and ondansetron to block serotonin receptors and prevent nausea and vomiting.
Dexamethasone, Ondansetron, Aprepitant · Ottawa Hospital Research Institute · Oncology / Supportive Care
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different mechanisms: glucocorticoid, 5-HT3 antagonist, and NK1 antagonist pathways.

Phase 3 pipeline (4)

palonosetron, dexamethasone, and 0.9% NaCl · Sixth Affiliated Hospital, Sun Yat-sen University · Oncology
Palonosetron blocks serotonin 5-HT3 receptors, while dexamethasone has anti-inflammatory and antiemetic effects, and 0.9% NaCl provides hydration and electrolyte balance.
Dexamethasone+NK-1 RA+5-HT3 RA · Fifth Affiliated Hospital, Sun Yat-Sen University · Oncology (supportive care)
This triple-agent combination blocks chemotherapy-induced nausea and vomiting (CINV) through corticosteroid anti-inflammatory action, neurokinin-1 receptor antagonism, and serotonin 5-HT3 receptor antagonism.
Aprepitant+palonosetron+dexamethasone · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Oncology
This combination blocks chemotherapy-induced nausea and vomiting (CINV) through three complementary pathways: NK1 receptor antagonism, 5-HT3 receptor antagonism, and glucocorticoid anti-inflammatory effects.
Ondansetron, dexamethasone, aprepitant · University of Oklahoma · Oncology
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different molecular pathways.

Phase 2 pipeline (1)

Antiemetic Combinations · Tasnem Abo-elouon · Oncology
Combination of antiemetic drugs to prevent nausea and vomiting.

Patent intelligence

antiemetic combination patent landscape — aggregated cliff calendar, attackable patents, originator estates